These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24324057)

  • 1. DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer.
    Moritz R; Ellinger J; Nuhn P; Haese A; Müller SC; Graefen M; Schlomm T; Bastian PJ
    Anticancer Res; 2013 Dec; 33(12):5249-54. PubMed ID: 24324057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
    Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
    Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
    Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
    Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
    Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
    Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
    Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH; Lee S; Lee HJ; Hwang KS
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy.
    Jentzmik F; Krause H; Reichelt U; Schrader AJ; Schrader M; Baumunk D; Cash H; Miller K; Schostak M
    World J Urol; 2012 Aug; 30(4):541-6. PubMed ID: 21947551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
    Ellinger J; El Kassem N; Heukamp LC; Matthews S; Cubukluoz F; Kahl P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
    J Urol; 2008 Jan; 179(1):346-52. PubMed ID: 18006010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
    Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
    Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
    Bernardini S; Miano R; Iori R; Finazzi-Agrò E; Palmieri G; Ballerini S; Angeloni C; Orlandi A; Bellincampi L; Cortese C; Federici G
    Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
    Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
    J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.